OCS
Oculis Holding·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
RSI Oversold
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OCS
Oculis Holding Ag
A company that develops drugs to treat eye diseases
Chemical and pharmaceutical
12/11/2017
05/18/2021
NASDAQ Stock Exchange
60
12-31
Common stock
Bahnhofstrasse 20, CH-6300 Zug, Switzerland
Develops drugs for ophthalmic and neuro-ophthalmic diseases.
Oculis Holding AG was incorporated under the laws of Switzerland on December 11, 2017. The Company is a clinical-stage biopharmaceutical company headquartered in Switzerland with extensive expertise in therapies for the treatment of eye diseases and is involved in the development of innovative drug candidates with the potential to address many eye diseases. Their focus is on advancing therapeutic candidates to treat major ophthalmic diseases that lead to vision loss, blindness or reduced quality of life. Their clinical portfolio currently includes three therapeutic drug candidates: OCS-01, OCS-02 and OCS-05.
Company Financials
EPS
OCS has released its 2025 Q4 earnings. EPS was reported at -0.53, versus the expected -0.48, missing expectations. The chart below visualizes how OCS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
OCS has released its 2026 Q2 earnings report, with revenue of 383.57K, reflecting a YoY change of 16.66%, and net profit of -12.34M, showing a YoY change of 61.41%. The Sankey diagram below clearly presents OCS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
